Objective: This phase 3 study evaluated the endometrial safety of bazedoxifene (BZA)/conjugated estrogens (CE) and bone mineral density (BMD) effects vs BZA alone, hormone therapy, and placebo (PBO).
combine the efficacy of estrogens on menopausal symptoms and prevention of postmenopausal bone loss with the protective effects of a selective estrogen receptor modulator on the reproductive tract and breast (6) .
The first TSEC in clinical development pairs bazedoxifene (BZA) with conjugated estrogens (CE). The efficacy of BZA/CE has been evaluated in the phase 3 Selective estrogens, Menopause, And Response to Therapy (SMART) trials (7) (8) (9) (10) (11) (12) (13) (14) (15) . In brief, BZA 20 mg/CE 0.45 and 0.625 mg have demonstrated beneficial effects on vasomotor symptoms, vulvar/vaginal atrophy (VVA), bone, sleep, and quality of life relative to those with placebo (PBO), while at the same time maintaining endometrial and breast safety with no effect on mammographic breast density in postmenopausal women with an intact uterus.
The SMART-5 trial evaluated the endometrial safety of BZA 20 mg/CE 0.45 and 0.625 mg and their efficacy in preventing bone loss over 12 months in postmenopausal women with an intact uterus, compared with PBO, BZA 20 mg, and combined continuous EPT with CE 0.45 mg/ medroxyprogesterone acetate (MPA) 1.5 mg. This report describes the primary trial results, including endometrial safety and bone density results.
Materials and Methods
The SMART-5 trial was a 1-year, multicenter, international, randomized, double-blind, PBO-and active-controlled phase 3 study conducted at 166 sites. This study enrolled generally healthy, postmenopausal women aged 40 to 65 years seeking treatment for menopausal symptoms. Eligible subjects had a uterus, body mass index (BMI) Յ34.0 kg/m 2 , and endometrial biopsy results with no clinically abnormal finding on histologic interpretation obtained from sufficient tissue. This trial included an osteoporosis substudy (OSS) at sites that had access to Hologic or Lunar dual-energy x-ray absorptiometry (DXA) machines. Subjects were eligible for the OSS if they were Յ5 years past their last menstrual cycle and had 2 evaluable bone mineral density (BMD) scans at screening of the lumbar spine and total hip that differed by Ͻ5.0% and Ͻ7.5%, respectively (different criteria due to better precision of spine than hip scans). Subjects with lumbar spine or total hip T scores ϽϪ2.5 at screening or a current/history of osteoporosis or low-impact traumatic fracture were excluded from the substudy. All subjects provided written informed consent before enrollment. The study protocol, investigator's brochure, and informed consent form were approved by an institutional review board or an independent ethics committee at each site.
Subjects received daily oral BZA 20 mg/CE 0.45 or 0.625 mg, BZA 20 mg, CE 0.45 mg/MPA 1.5 mg, or PBO at a ratio of 2:2:1:1:2 based on a randomization schedule developed by Wyeth Research (now a subsidiary of Pfizer Inc). Randomization was stratified based on participation in the OSS using the Computerized Operations Randomization Environment II (CORE II) system. The BZA/CE, BZA, and CE/MPA tablets were overencapsulated to match PBO capsules for blinding. All subjects re-ceived 600 mg of elemental calcium and 400 IU of vitamin D daily.
The primary endpoint for the main study was the incidence of endometrial hyperplasia at 12 months. Secondary endpoints included cumulative amenorrhea, breast tenderness, and changes from baseline in breast density (breast density substudy) and sleep parameters (sleep substudy). Findings from the breast density and sleep substudies were reported separately. For the OSS, the primary endpoint was percent change from baseline in lumbar spine BMD at 12 months. Secondary endpoints included change from baseline in total hip BMD at 12 months, lumbar spine and total hip BMD at 6 months, and bone turnover marker (BTM) levels at 3, 6, and 12 months.
Endometrial hyperplasia was assessed by endometrial biopsies at screening and 12 months. Biopsy samples were analyzed centrally in a blinded fashion by 2 primary pathologists; if these pathologists disagreed, a third pathologist was consulted. Diagnosis was made based on agreement of Ն2 pathologists. Endometrial thickness was evaluated by transvaginal ultrasonography (TVU) at screening and 12 months. Incidence of endometrial hyperplasia was assessed in the prespecified efficacy evaluable (EE) population consisting of randomized subjects who received Ն1 dose of study drug, did not have endometrial hyperplasia at baseline, had endometrial biopsies at screening and month 12 or a diagnosis of endometrial hyperplasia before month 12, and had no major protocol violations. The incidence of endometrial hyperplasia at 12 months and the exact one-sided and two-sided 95% confidence intervals (CIs) were calculated for each group. For additional safety evaluation, a change in endometrial thickness was evaluated by an analysis of covariance (ANCOVA) with the baseline values as covariates.
Amenorrhea and breast tenderness were assessed using daily diaries. Amenorrhea data were evaluated in randomized subjects who received Ն1 dose of study drug and recorded Ն1 day of on-therapy data. Cumulative amenorrhea was defined as the percentage of subjects with no bleeding or spotting over consecutive 4-week cycles. Comparisons between the groups were made using the Fisher exact test. Breast tenderness was evaluated in randomized subjects who received Ն1 dose of study drug and had Ն20 days of data at screening and in Ն1 postbaseline 4-week interval to include subjects with more complete data per 28-day cycle. The percentage of subjects who reported Ն1 day of breast tenderness within each interval was calculated, and comparisons between the groups were made using the Cochran-Mantel-Haenszel test stratified by the baseline value.
BMD was evaluated by DXA at screening and at 6 and 12 months using Hologic and Lunar DXA machines. Cross-calibration within manufacturers was done at study initiation. Analysis and quality control were performed centrally at the Helen Hayes Hospital Bone Quality Control Center (West Haverstraw, New York). The central laboratory determined, based on the repeat baseline DXA scans, that the coefficient of variation was 1.2% for lumbar spine, 1.3% for total hip, and 1.5% for femoral neck. Lumbar spine BMD was measured at L2 to L4; L1 was measured if 1 of these vertebrae was abnormal. Fractured vertebrae were excluded. The percent change in BMD and BTM was prespecified to be assessed in randomized subjects who received Ն1 dose of study drug and had a baseline and Ն1 postscreening assessment (modified intent-to-treat population of the OSS). For BMD, a last observation carried forward method was used to impute postbaseline missing data. The percent change from baseline in BMD (lumbar spine, total hip, femoral neck, and tro-chanter areas) was evaluated by an ANCOVA with treatment and region as factors and baseline BMD and years since menopause as covariates. Pairwise between-group comparisons were performed using the Wald test. BMD responders were defined as subjects with no change or an increase from baseline in BMD at 12 months, and pairwise comparisons were performed using the Fisher exact test. For BTM, prespecified ranked percent change from baseline was evaluated using an ANCOVA with treatment and region as factors and baseline values as covariates.
Safety was assessed via scheduled physical examinations, endometrial biopsies, Pap smears, TVUs, mammograms, vital signs, electrocardiograms, and clinical laboratory determinations. Adverse events (AEs) were recorded throughout the study according to clinical trial guidelines (16) . Comparisons between the groups were performed using the Fisher exact test.
The sample size for the main study was determined based on acceptable endometrial hyperplasia incidence per regulatory agency guidance. Assuming that Ն70% of enrolled subjects would be analyzed, enrollment of 430 subjects each in the BZA/CE and PBO groups and 215 each in the BZA and CE/MPA groups was needed to analyze 300 and 150 subjects, respectively. This sample size was expected to provide Ն80% power to observe 0 or 1 event out of 300 events for primary comparisons, assuming a population rate of 0.26% for endometrial hyperplasia (16) . For the OSS, sample size determination was based on comparisons between the BZA/CE and PBO groups in changes in lumbar spine and total hip BMD. Inclusion of 42 and 84 subjects per group was needed to provide Ն90% power for lumbar spine and total hip BMD comparisons, respectively. With the assumption that 85% of enrolled subjects would be included in the analysis, 150 subjects each in the BZA/CE and PBO groups and 75 each in the BZA and CE/MPA groups would be enrolled.
Results

Subject disposition and demographics
Subject demographics, baseline characteristics, and osteoporosis risk factors were similar among the groups (Table 1). Subjects were primarily white (90%), with a mean age of 54.2 years, mean BMI of 26.1 kg/m 2 , and mean time since last menstrual period of 4.8 years. Of the 1886 subjects randomized to treatment, 1843 received Ն1 dose of the study drug and were included in the safety analyses ( Figure 1 ). Of these, 1375 (75%) were included in the EE population for endometrial hyperplasia analysis. The majority excluded from the EE population did not have an evaluable endometrial biopsy at month 12 (24% and 22% for BZA 20 mg/CE 0.45 and 0.625 mg, respectively; 27% for BZA 20 mg; 32% for CE/MPA; and 25% for PBO).
A total of 1477 (80.1%) subjects completed the study; the most common reasons for discontinuation were AEs (8%) and subject request (3.8%). There were no individual AEs that led to discontinuation of Ͼ3% of subjects in any treatment group. Rates of discontinuation were comparable among the BZA/CE, BZA, and PBO groups. The CE/MPA group had a higher incidence of overall and AErelated discontinuations (overall P Ͻ .05 for both), with a significantly higher percentage of subjects discontinuing due to breast tenderness (P ϭ .006), pelvic pain (P Ͻ .001), and vaginal hemorrhage (P Ͻ .001) vs the other groups. A total of 590 subjects were included in the OSS. One subject each from the BZA 20 mg/CE 0.625 mg and PBO groups was excluded because baseline BMD scans of the lumbar spine and total hip differed by Ͼ5.0% and Ͼ7.5%, respectively.
Endometrial safety
The incidence of endometrial hyperplasia at 12 months was low and similar among the groups, with low rates of atypia (Table 2 and Supplemental Table 1 published on The Endocrine Society's Journals Online web site at http:// jcem.endojournals.org). Rates of endometrial hyperplasia at 12 months were Ͻ1% with upper limits of the one-sided 95% CI Ͻ2.0 for all groups.
The BZA/CE and CE/MPA groups showed significantly greater increases from baseline in endometrial thickness vs the PBO group: the adjusted mean changes from baseline were 0.17 mm (P Ͻ .05), 0.51 mm (P Ͻ .001), and 0.78 mm (P Ͻ .001) for BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, and CE/MPA, respectively, compared with 0.09 mm for PBO and BZA 20 mg ( Table 2 ). The incidence of proliferative endometrium at 12 months was low (Ͻ1%) and similar among the groups. The incidence of endometrial polyps identified by endometrial biopsy was low in all groups 
Bleeding and breast tenderness
Based on diary data, subjects treated with BZA 20 mg/CE 0.45 or 0.625 mg and BZA 20 mg had high rates of cumulative amenorrhea over 13 consecutive 4-week cycles, similar to the rates for PBO (Figure 2A ). The CE/ MPA group showed significantly lower cumulative amenorrhea rates vs the other groups at all time points (P Ͻ .001). There were no differences in the percentage of subjects reporting Ն1 day of breast tenderness during 4-week cycles over 12 months between the BZA/CE and BZA groups vs the PBO group ( Figure 2B ). The CE/MPA group showed a significantly higher incidence of breast tenderness vs the PBO group (P Ͻ .001 for all time periods) and all other active treatment groups (P Ͻ .01 for all time periods).
BMD and BTMs
At 12 months, all active treatment groups had increases from baseline in lumbar spine BMD, whereas the PBO group lost BMD (adjusted mean ϮSE percent change from baseline of 0.24% Ϯ 0.29% for BZA 20 mg/CE 0.45 mg, 0.60% Ϯ 0.27% for BZA 20 mg/CE 0.625 mg, 0.07% Ϯ 0.40% for BZA 20 mg, 1.30% Ϯ 0.39% for CE/MPA, compared with a decrease of Ϫ1.28% Ϯ 0.28% for PBO; P Ͻ .01 vs PBO for all) ( Figure 3A and Supplemental Table   2 ). The BZA/CE and CE/MPA groups also showed significantly greater increases from baseline in lumbar spine BMD vs the PBO group at 6 months (P Ͻ .05 for all). At 12 months, the CE/MPA groups showed a significantly greater increase from baseline in lumbar spine BMD compared with BZA 20 mg/CE 0.45 mg and BZA 20 mg (P Ͻ .05). No significant differences in lumbar spine BMD were observed among active treatment groups at 6 months.
All active treatment groups showed significantly greater increases from baseline in total hip BMD vs the PBO group, which lost BMD at 6 and 12 months (P Ͻ .001 vs PBO) ( Figure 3B and Supplemental Table 2 ). Significantly greater improvement was also observed in femoral neck BMD for all active treatment groups vs the PBO group at 6 and 12 months except for the BZA 20 mg group at 6 months (P Ͻ .01) and in femoral trochanter BMD for all active treatment groups vs the PBO group at 6 and 12 months (P Ͻ .001). No differences were observed in total hip BMD among the active treatment groups at 6 and 12 months.
The BZA 20 mg/CE 0.45 mg (Ϫ40.86% and Ϫ42.38%) and BZA 20 mg/CE 0.625 mg (Ϫ50.06% and Ϫ43.58%) groups showed significantly greater decreases from the baseline in serum C-telopeptide and procollagen I N-terminal propeptide levels, respectively, vs the PBO (Ϫ5.52% and Ϫ11.13%, respectively) group at 12 months (P Ͻ .001 for all) (Figure 3 , C and D). Significant decreases with BZA/CE were also observed at 3 and 6 months. Significant decreases in BTM were also observed for BZA 20 mg at months 6 and 12 and for CE/MPA at months 3, 6, and 12 vs those for PBO (P Ͻ .01 for all). No differences were observed among groups in the incidences of fractures reported as AEs, although the study was only 12 months in duration and not powered for fracture detection.
Safety and tolerability
Overall, there were no differences among groups in incidences of AEs, treatment-emergent AEs (TEAEs), and serious AEs (Table 3) , although more subjects in the CE/MPA group (14.1%) discontinued the study due to AEs than subjects in other groups (7.0%-7.6%). The most commonly reported TEAEs were nasopharyngitis, back pain, pain in extremity, headache, breast tenderness, and vaginal hemorrhage. There were no differences among the groups in incidences of selected cardiac or cerebrovascular AEs. There was one report of deep vein thrombosis in the CE/MPA group; no cases of VTEs (including pulmonary embolism) were reported for the other groups.
There were no significant differences among the groups in breast cancer incidence at 12 months, with 2 cases reported for BZA 20 mg/CE 0.45 mg, 1 case each for CE/ MPA and PBO, and none for BZA 20 mg/CE 0.625 mg and BZA 20 mg (Table 3 ). There were also no differences among the groups in incidences of other breast-related AEs (including breast calcifications; breast cyst; breast disorder; breast mass; benign, malignant, or unspecified neoplasms; and abnormal mammograms), with 11 (2.5%) and 3 (0.6%) cases for BZA 20 mg/CE 0.45 and 0.625 mg, respectively, 4 (1.7%) for BZA 20 mg, 6 (2.7%) for CE/ MPA, and 8 (1.7%) for PBO.
The incidence of selected bleeding-related AEs in the BZA 20 mg/CE 0.45 and 0.625 mg groups (7.0% and 5.7%, respectively) was similar to that for the PBO group (8.4%) and lower than that for the CE/MPA group (22.3%; overall P Ͻ .001). The incidence of sim- ple ovarian cysts was similar among the groups ( Table  3 ). The incidence of clinically relevant ovarian cysts (diameter Ն20 mm) was similar among the groups, with 2 cases for BZA 20 mg/CE 0.45 mg, 5 for BZA 20 mg/CE 0.625 mg, 4 for BZA 20 mg, 1 for CE/MPA, and 2 for PBO.
Discussion
The TSEC BZA 20 mg/CE 0.45 and 0.625 mg is being evaluated as a novel alternative to combined EPT for symptomatic postmenopausal women with an intact uterus. This study assessed 2 doses of BZA/CE vs BZA monotherapy, CE 0.45 mg/MPA 1.5 mg, and PBO in postmenopausal women seeking treatment for menopausal symptoms. BZA 20 mg/CE 0.45 and 0.625 mg showed low incidences of endometrial hyperplasia at 12 months (similar to those with PBO) with significant improvements in lumbar spine and total hip BMD (vs BMD losses with PBO) and significant decreases from baseline in BTMs vs those with PBO. BZA/CE was associated with low incidences of bleeding and breast pain, similar to those with PBO and BZA alone and lower vs CE/MPA. Incidences of AEs, TEAEs, and serious AEs for BZA/CE were similar to those with PBO. BZA/CE did not increase incidences of cardiac or cerebrovascular events, and no VTEs were reported with BZA/CE. Incidences of breast carcinoma and other breast-related and gynecologic AEs were similar among the groups. These results are consistent with findings from previous SMART trials (7) (8) (9) (10) (11) (12) (13) (14) showing that BZA 20 mg/CE 0.45 and 0.625 mg is effective in treating menopausal symptoms and preventing bone loss while protecting the endometrium, with a favorable safety/tolerability profile.
Low rates of endometrial hyperplasia and proliferative endometrium (Ͻ1% for both) at 12 months for BZA/CE were similar to those with PBO and are consistent with findings from the SMART-1 trial (10) . Inclusion of CE 0.45 mg/MPA 1.5 mg in this study allowed direct comparisons between BZA/CE and a conventional EPT (CE alone could not be given due to safety concerns in women with an intact uterus). There were no differences between BZA/CE and CE/MPA in the incidence of endometrial hyperplasia at 12 months. BZA/CE had a nonclinically significant increase in endometrial thickness that was lower than that observed with CE/MPA. The overall incidence of endometrial polyps was low, and none of the polyps identified in the BZA/CE groups at 12 months had atypia. Endometrial hyperplasia, including atypia, and endometrial polyps have been reported with the use of systemic estradiol, but not vaginal estrogens, when combined with raloxifene (17) (18) (19) . In contrast, this 1-year study showed that BZA protected the endometrium from CE stimulation, with no differences in the incidence of atypia in endometrial biopsy samples or polyp pathology vs PBO.
In this 12-month study of symptomatic postmenopausal women, small increases in BMD of the lumbar spine and total hip were observed with BZA 20 mg/CE 0.45 mg (mean adjusted difference vs PBO of 1.51 and 1.21, respectively) and BZA 20 mg/CE 0.625 mg (1.87 and 1.60, respectively), whereas significant BMD losses were observed with PBO (P Ͻ .001 for all). These results show prevention of postmenopausal bone loss with BZA/CE in women with relatively normal BMD at the study onset, who are at risk for bone loss. These findings are similar to BMD changes observed in the 2-year pivotal BZA/CE study (SMART-1), the Women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial of CE/MPA, and the Multiple Outcomes of Raloxifene Evaluation (MORE) (20 -22) . Importantly, the mean adjusted differences vs PBO in lumbar spine BMD with BZA/CE (approximately 1.5%-2%) are similar to BMD changes shown to be associated with vertebral fracture risk reductions in the BZA and MORE pivotal fracture studies (20, 22) . The increase in lumbar spine BMD for CE/MPA was significantly greater than that for BZA 20 mg/CE 0.45 mg at 12 months; no other differences were observed among the BZA/CE and CE/MPA groups in lumbar spine or total hip BMD (Figure 3) . Because BZA and CE bind to the same receptor (23) and CE is a more potent antiresorptive agent, one may expect attenuation in BMD responses when BZA is added to CE, similar to that observed in the SMART-1 trial when BZA doses increased from 10 to 40 mg (8) . The magnitude of this attenuation and its clinical relevance as to risk of osteoporotic fractures compared with that seen with continuous combined hormone therapy remain to be established. Despite the attenuation of skeletal effects in lumbar spine compared with those with CE/MPA, when compared with PBO, both BZA/CE doses provided significant and clinically meaningful effects on BMD, with BTM reductions ( Figure 3 ) similar to that observed with bisphosphonates (24) . BZA/CE-treated subjects had significantly higher rates of cumulative amenorrhea, lower incidences of bleedingrelated AEs, and lower rates of breast tenderness vs CE/ MPA. A significantly higher proportion of CE/MPAtreated subjects discontinued treatment due to breast tenderness, pelvic pain, and vaginal hemorrhage vs those receiving BZA/CE. The increased incidence of bleeding and breast pain observed for CE/MPA vs PBO is consistent with previous findings that EPT is associated with breast stimulation (2) and irregular vaginal bleeding (3, 4) . In addition, increased rates of discontinuation with CE/MPA are consistent with previous findings that tolerability issues contribute to discontinuation of EPT (25, 26) . These findings suggest that BZA 20 mg/CE 0.45 and 0.625 mg may provide improved bleeding-and breast-related tolerability vs CE/MPA. In addition, in prior SMART trials, BZA/CE significantly decreased the mean daily number and severity of hot flushes vs PBO (9, 11) and relieved moderate to severe VVA and vaginal symptoms (9, 14) . Overall, the results from this and earlier studies (12, 13) suggest that BZA/CE may improve quality of life.
The overall rates of study discontinuation were low and consistent with those from the Postmenopausal Estrogen/ Progestin Interventions trial of hormone therapy (27) . The most common reason for excluding study participants from evaluation in the current trial was lack of an evaluable 12-month biopsy; this requirement was based on regulatory guidance (16) .
Limitations of the current study include the facts that most study participants were white and that the BMI in-clusion criterion of Յ34.0 kg/m 2 prevented enrollment of morbidly obese participants. The study provided direct comparisons between BZA/CE and the currently approved CE/MPA but did not include a CE-only arm because of concerns about uterine safety with unopposed estrogens; thus, no comparisons can be drawn between CE alone and BZA/CE. The study duration was 1 year, which may have limited the BMD response. BMD and BTM are surrogate endpoints for fractures, and although we observed clinically relevant changes in the bone markers, the effect on fracture risk reduction will need to be determined from properly powered fracture trials. These factors suggest the importance of conducting a longer future study in a mixed ethnic population to further evaluate endometrial safety, BMD response, and fracture prevention.
To summarize, BZA 20 mg/CE 0.45 and 0.625 mg showed low rates of endometrial hyperplasia and proliferative endometrium, positive effects on BMD but numerically lower than that seen with CE/MPA, robust decreases in BTMs, and an overall favorable safety/tolerability profile in postmenopausal women over 12 months of treatment, with significantly lower incidences of bleeding and breast pain compared with CE/MPA. Together with previous findings demonstrating efficacy on vasomotor symptoms and VVA (9, 11, 14) and neutral effects on mammographic breast density (15, 28) , these results suggest that BZA/CE is a novel, safe, and promising therapy for postmenopausal women with an intact uterus seeking treatment for menopausal symptoms and prevention of bone loss. It may offer particular advantages to women for whom endometrial safety is a key concern and those who do not want to initiate a therapy that contains progestins.
